Search

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Research & Mentoring

One of EHA’s key pillars is investing in future leaders in hematology.

Read more

Future

You may find below an overview of the dates and locations of the future EHA Congresses.  
For information on future congresses, please contact Connect at a. congress@ehaweb.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Read more

EHA2024 Hybrid Congress

Thank you all for joining us in Madrid for the 29th European Hematology Association Congress!

The EHA2024 Congress platform is now closed. You may browse selected content through the EHA Library, EHA Open access library.

Read more